Amgen recorded solid upward price movement following the company’s announcement of positive topline results from its pivotal Phase 3 OASIZ 301 clinical trial. The study evaluated dazodalibep in adult patients suffering from Sjögren’s disease with moderate-to-severe systemic disease activity. The trial successfully met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in systemic disease activity compared to placebo over a 48-week evaluation period, with noticeable improvements emerging as early as four weeks into treatment. Because Sjögren’s disease currently lacks any FDA-approved systemic disease-modifying therapies, this successful late-stage readout positions dazodalibep as a…